Gabriel Capellá is the group leader of Hereditary Cancer Group in Oncobell, a multidisciplinary research group which has been working in a clinical setting for over 20 years (Hereditary Cancer Programme of the Catalan Institute of Oncology) which provides genetic advice on cancer and molecular tests. The group’s research focusses on improving healthcare for patients…
Read MoreAutor: oncobell
Ernest Nadal, group leader of Clinical Research in Solid Tumors Group, talks about his research in Oncobell
Ernest Nadal, along with Josep Mª Piulats, is the group leader of Clinical Research in Solid Tumours Group in Oncobell. His team’s aim is to transform ideas and hypotheses generated in the cancer-treatment environment into personalised therapies, clinical trials and translation projects. This leads to an increase in the social and bibliometric impact of the research…
Read MoreDiscover Barcelona
Come to the first symposium organized by Oncobell and take the opportunity to discover Barcelona: in this article you will find the perfect guide to get around the city. Barcelona has a network of municipal markets that includes 39 food markets spread round all the city neighbourhoods and characterised by their fresh food, personal service,…
Read MoreJosep MªPiulats, chairman of Clinical Research table, presents his cancer research
Josep Maria Piulats is the group leader of the Clinical Research in Solid Tumours group of Oncobell, within Idibell. His group is striving to become the gateway to purely translational/clinical research generated at the ICO and the academic pathway to introducing new treatments. The team’s aim is to transform ideas and hypotheses generated in the…
Read MoreAlberto Villanueva talks about his cancer research in Oncobell
Alberto Villanueva is the group leader of Chemoresistance and predective factors to tumor response and stromal microenvirontment group in Oncobell. His research in cancer is based on the Orthoxenografts®, experimental mouse models in which a small piece of human tumour is implanted (implantation from one spices to another, xenograft) in the same organ of origin…
Read MoreGeorge Thomas presents his research and lecture
LECTURE: He is going to talk about Targeting the IRBC in c-Myc driven tumors in the first Oncobell Symposium. BIOGRAPHY: George Thomas is acknowledged as an innovative leader in the field of signal transduction and growth control based on his seminal studies on the discovery and regulation of the 40S ribosomal protein S6 kinase (S6K1), and more…
Read MoreXavier Matias Guiu presents the research of the Gynecologic Cancer Group (Oncobell)
Xavier Matias-Guiu, group leader of the Gynecologic Cancer Group within Oncobell, presents the strategic lines, the current projects and the future goals of his research. The Gynaecological Cancer group is a multidisciplinary team made up of gynaecologists, oncologists, pathologists and basic researchers. The group has three leaders: Xavier Matias-Guiu, who also leads the CIBER group…
Read MoreJoan Seoane answers our interview
Joan Seoane is a Group Leader and Director of the Translational Research program at the Vall d’Hebron Institute of Oncology (VHIO) within the Vall d’Hebron University Hospital since 2011. In 1998, Joan obtained his PhD in Biochemistry and Molecular Biology from the University of Barcelona. Previously, in 1993, he obtained his BSc degree in Chemistry.…
Read MoreVictor Moreno presents his research and lecture
Victor Moreno is group leader of the Colorectal Cancer Group at Oncobell, Professor of Preventive Medicine at the University of Barcelona and Director of the Cancer Prevention and Control Program at the Catalan Institute of Oncology. His main research area is cancer prevention, with special interest in colorectal cancer (CRC). He performs studies on genetic and molecular epidemiology aiming to…
Read MoreMark Rubin answers our interview
Prof. Mark Rubin is a leader in the fields of prostate cancer biology and precision medicine as it applies to all cancers. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Prof. Rubin has translated many of…
Read More